Monograph

V03AF01 - Mesna

Propably not porphyrinogenic

Rationale

Non-hepatic, probably non-CYP metabolism.

Chemical description

Sodium mercaptethane sulfonate administered during treatment with iophosphamide in order to counteract urinary tract toxicity caused by acroleine formed. Converted to free thiol in serum and eliminated in urine.

Similar drugs

Explore alternative drugs in similar therapeutic classes V03A / V03AF or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Uromitexan · Uromitexan, omhulde tablet, 400 mg · Uromitexan, omhulde tablet, 600 mg · Uromitexan, oplossing voor injectie 100 mg/ml · Uromitexan, oplossing voor injectie, 100 mg/ml

Belgium

Uromitexan · Uromitexan 400 mg/4 ml sol. inj. i.v. amp.

United Kingdom

Mesna · Mesna 1g/10ml solution for injection ampoules · Mesna 400mg tablets · Mesna 400mg/4ml solution for injection ampoules · Mesna 40mg/5ml oral solution · Mesna 600mg tablets · Uromitexan · Uromitexan 1g/10ml solution for injection ampoules · Uromitexan 400mg tablets · Uromitexan 400mg/4ml solution for injection ampoules · Uromitexan 600mg tablets

Denmark